Continuation rates of the subdermal contraceptive Implanon® and associated influencing factors

European Journal of Contraception and Reproductive Health Care

Volumn 19, Issue 1, 2014, Pages 15-21

  Teunissen, Anna Maria ^a   Grimm, Bernd ^b   Roumen, Frans J M E ^b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Zuyderland Medical Centre   (Netherlands)

Author keywords

Continuation rate; Counselling; Discontinuation rate; Etonogestrel; Implanon ; Irregular bleeding; Subdermal contraceptive implant

Indexed keywords

COPPER INTRAUTERINE DEVICE; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETONOGESTREL; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT;

ACNE; ADOLESCENT; ADULT; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; DEVICE REMOVAL; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FOLLOW UP; HORMONAL CONTRACEPTION; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; MOOD CHANGE; NETHERLANDS; NULLIPARA; OUTPATIENT; PATIENT COUNSELING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; TREATMENT WITHDRAWAL; WEIGHT GAIN; YOUNG ADULT;

ADOLESCENT; ADULT; COHORT STUDIES; CONTRACEPTIVE AGENTS, FEMALE; DESOGESTREL; DRUG IMPLANTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; METRORRHAGIA; MIDDLE AGED; NETHERLANDS; PARITY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84893435532     PISSN: 13625187     EISSN: 14730782     Source Type: Journal    
DOI: 10.3109/13625187.2013.862231     Document Type: Review

References (20)

1. Haimovich S. Profile of long-Acting reversible contraception users in Europe. Eur J Contracept Reprod Health Care 2009;14:187-95
2. Graesslin O , Korver T. The contraceptive effi cacy of Implanon ®:A review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care 2008;13(Suppl. 1):4-12
3. Croxatto H B, Mäkäräinen L. The pharmacodynamics and effi cacy of Implanon. An overview of the data. Contraception 1998;58:91S-97S.
4. Blumenthal P D , Gemzell-Danielsson K , Marintcheva- Petrova M. Tolerability and clinical safety of Implanon ®. Eur J Contracept Reprod Health Care 2008;13(Suppl. 1):29-36
5. Darney P , Patel A , Rosen K , et al. Safety and effi cacy of a single-rod etonogestrel implant (Implanon): Results from 11 international clinical trials. Fertil Steril 2009;91:1646-53
6. Laban M, AbdAlhamid M, Ibrahim EA , et al. Endometrial histopathology, ovarian changes and bleeding patterns among users of long-Acting progestin-only contraceptives in Egypt. Eur J Contracept Reprod Health Care 2012;17:451-7
7. Jeffreys LA, Clark AL. A successful approach to long-Acting contraceptive implants in primary care. Contraception 2012;85:381-3
8. Mansour D , Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon ® on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008;13(Suppl. 1):13-28
9. Casey P M, Long M E, Marnach M L, et al. Association of body mass index with removal of etonogestrel subdermal implant. Contraception 2013;87:370-4
10. Casey PM, Long ME, Marnach ML, Bury JE. Bleeding related to etonogestrel subdermal implant in a US population. Contraception 2011;83:426-30
11. Lakha F , Glasier A F. Continuation rates of Implanon ® in the UK: Data from an observational study in a clinical setting. Contraception 2006;74:287-9
12. Riney S , O'Shea B, Forde A. Etonogestrel implant as a contraceptive choice: Patient acceptability and adverse effect Profile in a general practice setting. Ir Med J 2009;102:24-5
13. Ezegwui HU, Ikeako LC, Ishiekwene CI , Oguanua TC. The discontinuation rate and reasons for discontinuation of Implanon at the family planning clinic of University of Nigeria Teaching Hospital (UNTH) Enugu, Nigeria. Niger J Med. 2011;20:448-50
14. Harvey C , Seib C , Lucke J. Continuation rates and reasons for removal among Implanon users accessing two family planning clinics in Queensland, Australia. Contraception 2009;80:527-32
15. Short M , Dallay D , Omokanye S , et al. Acceptability of the levonorgestrel releasing-intrauterine system and etonogestrel implant: One-year results of an observational study. Eur J Contracept Reprod Health Care 2012;17:79-88
16. Rubenstein J, Rubenstein P, Barter J, Pittrof R. Counselling styles and their effect on subdermal contraceptive implant continuation rates. Eur J Contracept Reprod Health Care 2011;16:225-8
17. Mansour D , Bahamondes L , Critchley H , et al. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. Contraception 2011;83:202-10
18. Weisberg E , Hickey M, Palmer D , et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 2009;24:1852-61
19. Vitzthum VJ, Ringheim K. Hormonal contraception and physiology: A research-based theory of discontinuation due to side effects. Stud Fam Plann 2005;36:13-32
20. Bitzer J , Gemzell-Danielsson K , Roumen F , et al. The CHOICE study: Effect of counselling on the selection of combined hormonal contraceptive methods in 11 countries. Eur J Contracept Reprod Health Care 2012;17:65-78